Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Characterization of Vero cell growth and death in bioreactor with serum-containing and serum-free media.

Quesney S, Marvel J, Marc A, Gerdil C, Meignier B.

Cytotechnology. 2001 Mar;35(2):115-25. doi: 10.1023/A:1017589526145.

2.

Kinetics and metabolic specificities of Vero cells in bioreactor cultures with serum-free medium.

Quesney S, Marc A, Gerdil C, Gimenez C, Marvel J, Richard Y, Meignier B.

Cytotechnology. 2003 May;42(1):1-11. doi: 10.1023/A:1026185615650.

3.

Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate.

Ferrier-Rembert A, Drillien R, Meignier B, Garin D, Crance JM.

Vaccine. 2007 Nov 28;25(49):8290-7. Epub 2007 Oct 11.

PMID:
17964011
4.

Industrial experience with live polio vaccine prepared on the Vero continuous cell line.

Meignier B.

Dev Biol (Basel). 2001;106:341-2; discussion 343-4. No abstract available.

PMID:
11761247
5.

Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida.

Salmon-Céron D, Excler JL, Finkielsztejn L, Autran B, Gluckman JC, Sicard D, Matthews TJ, Meignier B, Valentin C, El Habib R, Blondeau C, Raux M, Moog C, Tartaglia J, Chong P, Klein M, Milcamps B, Heshmati F, Plotkin S.

AIDS Res Hum Retroviruses. 1999 May 1;15(7):633-45.

PMID:
10331442
6.

Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV.

Tartaglia J, Excler JL, El Habib R, Limbach K, Meignier B, Plotkin S, Klein M.

AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S291-8. Review. No abstract available.

PMID:
9814957
7.

Fine specificity of anti-V3 antibodies induced in chimpanzees by HIV candidate vaccines.

Coëffier E, Girard M, Barré-Sinoussi F, Meignier B, Muchmore E, Fultz PN, LeClerc C.

AIDS Res Hum Retroviruses. 1998 Aug 10;14(12):1023-34.

PMID:
9718117
8.

Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines.

Coëffier E, Excler JL, Kieny MP, Meignier B, Moste C, Tartaglia J, Pialoux G, Salmon-Céron D, Leclerc C.

AIDS Res Hum Retroviruses. 1997 Nov 20;13(17):1471-85.

PMID:
9390746
9.

Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus.

Girard M, van der Ryst E, Barré-Sinoussi F, Nara P, Tartaglia J, Paoletti E, Blondeau C, Jennings M, Verrier F, Meignier B, Fultz PN.

Virology. 1997 May 26;232(1):98-104.

10.

Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain.

Girard M, Yue L, Barré-Sinoussi F, van der Ryst E, Meignier B, Muchmore E, Fultz PN.

J Virol. 1996 Nov;70(11):8229-33.

11.

African green monkey kidney (Vero) cells provide an alternative host cell system for influenza A and B viruses.

Govorkova EA, Murti G, Meignier B, de Taisne C, Webster RG.

J Virol. 1996 Aug;70(8):5519-24.

12.

Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system.

Fries LF, Tartaglia J, Taylor J, Kauffman EK, Meignier B, Paoletti E, Plotkin S.

Vaccine. 1996 Apr;14(5):428-34.

PMID:
8735555
13.

Antiplatelet antibodies during the course of HIV-preventive vaccine trial.

Kaplan C, Morel-Kopp MC, Kieny MP, Kolbe H, Salmon P, Sicard D, Pialoux G, Meignier B, Excler JL, Plotkin S.

AIDS. 1996 Apr;10(4):447-9. No abstract available.

PMID:
8728055
14.

Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers.

Salmon-Céron D, Excler JL, Sicard D, Blanche P, Finkielstzjen L, Gluckman JC, Autran B, Matthews TJ, Meignier B, Kieny MP, et al.

AIDS Res Hum Retroviruses. 1995 Dec;11(12):1479-86.

PMID:
8679292
15.

Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1.

Girard M, Meignier B, Barré-Sinoussi F, Kieny MP, Matthews T, Muchmore E, Nara PL, Wei Q, Rimsky L, Weinhold K, et al.

J Virol. 1995 Oct;69(10):6239-48.

16.

Replication of influenza A viruses in a green monkey kidney continuous cell line (Vero).

Govorkova EA, Kaverin NV, Gubareva LV, Meignier B, Webster RG.

J Infect Dis. 1995 Jul;172(1):250-3.

PMID:
7797924
17.

Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species.

Taylor J, Meignier B, Tartaglia J, Languet B, VanderHoeven J, Franchini G, Trimarchi C, Paoletti E.

Vaccine. 1995 Apr;13(6):539-49.

PMID:
7483774
18.

A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

Pialoux G, Excler JL, Rivière Y, Gonzalez-Canali G, Feuillie V, Coulaud P, Gluckman JC, Matthews TJ, Meignier B, Kieny MP, et al.

AIDS Res Hum Retroviruses. 1995 Mar;11(3):373-81. Erratum in: AIDS Res Hum Retroviruses 1995 Jul;11(7):875.

PMID:
7598771
19.

The safety and use of canarypox vectored vaccines.

Plotkin SA, Cadoz M, Meignier B, Méric C, Leroy O, Excler JL, Tartaglia J, Paoletti E, Gonczol E, Chappuis G.

Dev Biol Stand. 1995;84:165-70.

PMID:
7796950
20.

Highly attenuated poxvirus vectors: NYVAC, ALVAC and TROVAC.

Paoletti E, Taylor J, Meignier B, Meric C, Tartaglia J.

Dev Biol Stand. 1995;84:159-63. Review.

PMID:
7796949
21.

Early region 3-replacement adenovirus recombinants are less pathogenic in cotton rats and mice than early region 3-deleted viruses.

Berencsi K, Uri A, Valyi-Nagy T, Valyi-Nagy I, Meignier B, Peretz FV, Rando RF, Plotkin SA, Gönczöl E.

Lab Invest. 1994 Sep;71(3):350-8.

PMID:
7933985
22.

Highly attenuated poxvirus vectors.

Tartaglia J, Cox WI, Taylor J, Perkus M, Riviere M, Meignier B, Paoletti E.

AIDS Res Hum Retroviruses. 1992 Aug;8(8):1445-7. No abstract available.

PMID:
1466978
23.

Immunisation with canarypox virus expressing rabies glycoprotein.

Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, Paoletti E, Plotkin S.

Lancet. 1992 Jun 13;339(8807):1429-32.

PMID:
1351126
24.

NYVAC: a highly attenuated strain of vaccinia virus.

Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, Davis SW, van der Hoeven J, Meignier B, Riviere M, et al.

Virology. 1992 May;188(1):217-32.

PMID:
1566575
26.

Herpes simplex vaccines.

Whitley RJ, Meignier B.

Biotechnology. 1992;20:223-54. Review. No abstract available.

PMID:
1318135
27.

Genetically engineered attenuated herpes simplex viruses.

Meignier B.

Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S895-7. Review.

PMID:
1780614
28.

Comparison of lung histopathology and bronchoalveolar lavage cytology in mice and cotton rats infected with respiratory syncytial virus.

Vaux-Peretz F, Meignier B.

Vaccine. 1990 Dec;8(6):543-8. Erratum in: Vaccine 1991 Jan;9(1):70.

PMID:
2087875
30.

Molecular genetics of the rotaviruses.

Cohen J, Meignier B, Plotkin SA.

Vaccine. 1990 Jun;8(3):294-5. No abstract available.

PMID:
1973014
31.

Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers.

Gonczol E, Ianacone J, Ho WZ, Starr S, Meignier B, Plotkin S.

Vaccine. 1990 Apr;8(2):130-6.

PMID:
2159679
32.
33.
34.

Immunization against viral infections associated with human cancer: the promise of modern biotechnology.

Roizman B, Meignier B.

CA Cancer J Clin. 1988 Mar-Apr;38(2):95-103. No abstract available.

35.

Virulence of and establishment of latency by genetically engineered deletion mutants of herpes simplex virus 1.

Meignier B, Longnecker R, Mavromara-Nazos P, Sears AE, Roizman B.

Virology. 1988 Jan;162(1):251-4.

PMID:
2827384
36.
37.

Analyses of transplanted murine tumors for HSV DNA sequences.

Yehiely F, Thuning C, Meignier B, Norrild B, Warren J, Nahmias AJ, Rapp F, Roizman B, Frenkel N.

Int J Cancer. 1986 Sep 15;38(3):395-403.

PMID:
3017868
38.

Failure to induce cervical cancer in mice by long-term frequent vaginal exposure to live or inactivated herpes simplex viruses.

Meignier B, Norrild B, Thuning C, Warren J, Frenkel N, Nahmias AJ, Rapp F, Roizman B.

Int J Cancer. 1986 Sep 15;38(3):387-94.

PMID:
3017867
41.

Herpes simplex virus vaccines.

Meignier B, Roizman B.

Antiviral Res. 1985;Suppl 1:259-65. No abstract available.

PMID:
3002260
42.

Colonization of murine ganglia by a superinfecting strain of herpes simplex virus.

Meignier B, Norrild B, Roizman B.

Infect Immun. 1983 Aug;41(2):702-8.

43.

Application of molecular genetics to the design of live herpes simplex virus vaccines.

Roizman B, Warren J, Thuning CA, Fanshaw MS, Norrild B, Meignier B.

Dev Biol Stand. 1982;52:287-304.

PMID:
6299836
44.

Foot and mouth disease virus production on microcarrier-grown cells.

Meignier B, Mougeot H, Favre H.

Dev Biol Stand. 1980;46:249-56.

PMID:
6245001
45.

Supplemental Content

Loading ...
Support Center